Leadership Team

Andrew is a proven leader with over thirty years of experience building and managing teams at the intersection of the physical and computational sciences with medicine and biology, most recently serving as InterVenn's General Manager and Executive Vice President of Operations. He possesses in-depth and working knowledge in strategic planning, clinical research and trials, operations, project management, technology transfer and business/partnership development. Prior to InterVenn, Andrew was the Chief Science Officer at Standard BioTools, Inc (formerly Fluidigm), and was the liaison and bridge to the research community, identifying opportunities to address unmet needs in human health. He also served as the Genomics Business Unit Leader and was responsible for Product Marketing and Product Management.

Andrew also was the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research and held faculty positions in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. Andrew oversaw the operation of the shared services for the Kimmel Cancer Center and his research focused on systems biology approaches and mass spectrometry to understanding mechanisms of resistance to treatment of breast cancer and biomarkers of response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology.

Dan is the Chief Data Officer at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. After joining in late 2017, his team was responsible for training, deploying, and publishing the world's first neural network for mass spectrometry peak selection and integration.

Prior to starting at InterVenn, Dan led analytical efforts for dozens of scientific publications in cancer, neurodegenerative disease, and cardiovascular health at the Mayo Clinic. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Master's in Applied Statistics from Penn State. His team continues development on advanced machine learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

Kaitlynn Moser is a clinical operations leader with over a decade of experience driving innovation and improving patient outcomes. At InterVenn, she applies her expertise in clinical trials, strategic partnerships, and product development to bridge the gap between science and patient needs. Kaitlynn’s career is marked by a deep commitment to building high-performing, collaborative teams that deliver innovative solutions, accelerate clinical trial enrollment, forming longstanding partnerships and ultimately deliver products that improve patient outcomes.

Her career spans collaborations with start-ups, pharmaceutical companies, and academic medical centers, demonstrating deep expertise in clinical trials across Phases I-IV, post-marketing, and IIT/IIS with contributions to multiple therapeutic areas, including oncology, gynecology, and medical devices. Prior to joining InterVenn, Kaitlynn held multiple roles at the Mayo Clinic, where she advanced both translational and clinical research operations.